Next Article in Journal
Etomidate and Ketamine: Residual Motor and Adrenal Dysfunction that Persist beyond Recovery from Loss of Righting Reflex in Rats
Previous Article in Journal
Allosteric Modulation of GABAA Receptors by an Anilino Enaminone in an Olfactory Center of the Mouse Brain
Open AccessReview

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Jennifer Carew
Pharmaceuticals 2015, 8(1), 1-20; https://doi.org/10.3390/ph8010001
Received: 29 July 2014 / Accepted: 4 December 2014 / Published: 24 December 2014
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents. View Full-Text
Keywords: multiple myeloma; proteasome inhibitors; toxicity multiple myeloma; proteasome inhibitors; toxicity
MDPI and ACS Style

Merin, N.M.; Kelly, K.R. Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma. Pharmaceuticals 2015, 8, 1-20.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop